Aetna, a leading U.S. health care benefits company, has teamed with the University of South Florida, Georgetown University and the American Cancer Society to conduct a study on the use, outcomes and disparities associated with genetic testing for breast cancer and ovarian cancer among women.

According to a recent press release, the study, which is to be funded by Aetna, “will explore patterns of how and for what groups of women the available genetic tests for BRCA1 and BRCA2 mutations are being used in the community health care setting.”

Additionally, the study will examine the significant disparities that are suspected “to exist in the use of these tests among women of different socioeconomic, racial and ethnic groups.”

“This study may validate the need for specific strategies to eliminate barriers to these tests – whether they are knowledge-based, culturally-based, or access-based – and help improve the health outcomes among high-risk poor or minority women,” said Anne Beal, M.D., M.P.H., president of the Aetna Foundation.

Click here to read more about this landmark study.

Click here to read about Pathway’s Health Conditions Insight personal genetic screening, which includes screening for mutations associated with female breast cancer.

Comments are closed.